Brind.

Goldman Sachs resumed coverage of Pulmovant, a Roivant subsidiary, with a 'Buy' rating.

2 reports, 2 independent Updated Sep 9

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Goldman Sachs resumed coverage of Pulmovant, a Roivant subsidiary, with a 'Buy' rating.

Who's involved

What this event is mainly about

Goldman Sachs Roivant Sciences (United States)

Keep exploring

The entities involved

Goldman Sachs
American investment bank
- US-Iran truce aims to reopen Strait of Hormuz amid global monetary policy shifts and oil price drops.Mon 17:37
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
Roivant Sciences (United States)
company in New York, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Sep 9medicaldaily.com
Jul 25Insider MonkeyGoldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 10,